What Is the Mechanism Behind Increased Permeation Rate of a Poorly Soluble Drug from Aqueous Dispersions of an Amorphous Solid Dispersion?

2014 ◽  
Vol 103 (6) ◽  
pp. 1779-1786 ◽  
Author(s):  
Kerstin J. Frank ◽  
Ulrich Westedt ◽  
Karin M. Rosenblatt ◽  
Peter Hölig ◽  
Jörg Rosenberg ◽  
...  
2020 ◽  
Vol 21 (5) ◽  
Author(s):  
Cassiana Mendes ◽  
Rafael G. Andrzejewski ◽  
Juliana M. O. Pinto ◽  
Leice M. R. de Novais ◽  
Andersson Barison ◽  
...  

2017 ◽  
Vol 28 (5) ◽  
pp. 1316-1324 ◽  
Author(s):  
Shou-Cang Shen ◽  
Wai Kiong Ng ◽  
Jun Hu ◽  
Kumaran Letchmanan ◽  
Junwei Ng ◽  
...  

Folia Medica ◽  
2021 ◽  
Vol 63 (4) ◽  
pp. 557-568
Author(s):  
Vaishali P. Patel ◽  
Anita P. Patel ◽  
Ashish Shah

Febuxostat is a selective inhibitor of xanthine oxidase and belongs to BCS class II drugs having low solubility and high permeability. Solubility is the most important parameter which directly affects dissolution, absorption and bioavailability of the drugs. There are different techniques by which we can improve solubility and dissolution rate of poorly soluble drug. Amorphous solid dispersion is one of the methods which can improve solubility as well as powder characteristics. The aim of the present study was to formulate and optimize various methods of formulating solid dispersion by using various drug-to-polymer ratios and identifying the batch which gives higher solubility as well as amorphous powder of the drug febuxostat. Different techniques like hot melt method, solvent evaporation method and spray drying techniques were selected for optimization. Attempts were made to improve solubility of febuxostat by employing Kolliphor P 188, Kolliphor P 237, Eudragit RLPO in different drug-to-polymer ratios (1:1, 1:1.5, 1:2) as carrier. The prepared solid dispersion was characterized for the saturation solubility, percentage yield, using differential scanning calorimetry (DSC), scanning electron microscopy (SEM), powdered X-ray diffraction studies (PXRD), and residual solvent determination. Solid state characterization indicated that febuxostat was present in the amorphous form after mixing with polymeric carrier. In contrast to the pure form of drug, solid dispersion of the drug showed better solubility and amorphous characteristics which can be attributed to decreased crystallinity due to hydrotrophy. Thus, amorphous solid dispersion approach can be used successfully to enhance solubility, dissolution rate and bioavailability of febuxostat.


2012 ◽  
Vol 437 (1-2) ◽  
pp. 288-293 ◽  
Author(s):  
Kerstin J. Frank ◽  
Karin M. Rosenblatt ◽  
Ulrich Westedt ◽  
Peter Hölig ◽  
Jörg Rosenberg ◽  
...  

Author(s):  
Ahmed S. Abdul Jabbar

The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone  s630 was utilized. The HME raltegravir was formulated into tablet by direct compression method. The prepared tablets were assessed for all pre and post-compression parameters. The drug- excipients interaction was examined by FTIR and DSC. All formulas displayed complying with pharmacopoeial measures. The study reveals that formula prepared by utilizing drug and plasdone S630 at 1:1.5 proportion and span 20 at concentration about 30mg (trail-6) has given highest dissolution rate than contrasted with various formulas of raltegravir. Keywords: Hot melt extrusion, Raltegravir, Plasdone S630.


2008 ◽  
Vol 5 (6) ◽  
pp. 981-993 ◽  
Author(s):  
Michael Kennedy ◽  
Jack Hu ◽  
Ping Gao ◽  
Lan Li ◽  
Alana Ali-Reynolds ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document